WASHINGTON, D.C. (Date, 2021) – A new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Deloitte Center for Health Solutions outlines five critical strategies for enhancing diversity in clinical trials during the research and development of new medicines. The report, titled “Enhancing Clinical Trial Diversity: Stakeholder perspectives on advancing research through representative clinical trials”, is based on a year-long stakeholder engagement effort that has included research and feedback from more than 500 stakeholders across 150+ organizations, including community stakeholders, experts in clinical trials, racial justice experts, health practitioners and pharmaceutical companies.
“This research is an important step in our industry’s broader effort to address disparities within the U.S. health care system,” said Richard A. Moscicki, M.D., PhRMA’s executive vice president of science and regulatory advocacy and chief medical officer.
“Empowered patients and their families are better prepared to make informed choices about their health care and about participating in clinical trials. By working toward the strategies outlined in this report, we can help improve health outcomes in communities of color and help ensure people who want to participate in trials have the opportunities to do so.”
The five strategies outlined in the report build toward a community-based infrastructure and are key to building trust with communities to help ensure clinical trials better reflect patient populations:
Building trust and enhancing opportunities to participate in clinical trials are key steps in improving health equity. This community-based report serves as a resource as our industry continues work on this issue. Learn more at PhRMA.org/equity.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone.